Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.71 |
| ▸ | USP2 | O75604 | 2/20 | 0.71 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.71 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.71 |
| ▸ | LMNA | P02545 | 1/20 | 0.71 |
| ▸ | MMP9 | P14780 | 1/20 | 0.71 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.71 |
| ▸ | CA1 | P00915 | 16/20 | 0.42 |
| ▸ | CA2 | P00918 | 16/20 | 0.42 |
| ▸ | CA9 | Q16790 | 15/20 | 0.42 |
| ▸ | CA12 | O43570 | 5/20 | 0.42 |
| ▸ | CA7 | P43166 | 5/20 | 0.42 |
| ▸ | CA14 | Q9ULX7 | 5/20 | 0.42 |
| ▸ | CA3 | P07451 | 4/20 | 0.42 |
| ▸ | CA4 | P22748 | 4/20 | 0.42 |
| ▸ | CA6 | P23280 | 4/20 | 0.42 |
| ▸ | CA5A | P35218 | 4/20 | 0.42 |
| ▸ | CA5B | Q9Y2D0 | 4/20 | 0.42 |
| ▸ | RECQL | P46063 | 2/20 | 0.39 |
| ▸ | GLA | P06280 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29018669 | 1.00 | TSHR (0.71) | TSHRUSP2KDM4EALDH1A1LMNA | |
| SCHEMBL11401918 | 1.00 | TSHR (0.71) | TSHRUSP2KDM4EALDH1A1LMNA | |
| SCHEMBL1118535 | 0.98 | TSHR (0.75) | TSHRUSP2KDM4EALDH1A1LMNA | |
| SCHEMBL1607175 | 0.90 | — | — | |
| SCHEMBL4954793 | 0.87 | TSHR (0.94) | TSHRUSP2KDM4EALDH1A1LMNA | |
| SCHEMBL1335477 | 0.87 | TSHR (0.94) | TSHRUSP2KDM4EALDH1A1LMNA | |
| SCHEMBL4298840 | 0.87 | TSHR (0.94) | TSHRUSP2KDM4EALDH1A1LMNA | |
| SCHEMBL4952202 | 0.87 | TSHR (0.94) | TSHRUSP2KDM4EALDH1A1LMNA | |
| SCHEMBL8592211 | 0.87 | TSHR (0.94) | TSHRUSP2KDM4EALDH1A1LMNA | |
| SCHEMBL1931795 | 0.87 | TSHR (0.94) | TSHRUSP2KDM4EALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120088778-A1 | AZOLE DERIVATIVES AND FUSED BICYCLIC AZOLE DERIVATIVES AS THERAPEUTIC AGENTS | TRANSTECH PHARMA, INC. (US) | 2012-04-12 | — | — | US | disclosed |
| EP-1482931-B1 | MONO- AND BICYCLIC AZOLE DERIVATIVES THAT INHIBIT THE INTERACTION OF LIGANDS WITH RAGE | TRANSTECH PHARMA INC (US) | 2011-10-19 | — | — | EP | disclosed |
| US-20100256119-A1 | Azole derivatives and fused bicyclic azole derivatives as therapeutic agents | TRANSTECH PHARMA, INC. | 2010-10-07 | — | — | US | disclosed |
| US-7737285-B2 | Azole derivatives and fused bicyclic azole derivatives as therapeutic agents | TRANSTECH PHARMA, INC. (US) | 2010-06-15 | — | — | US | disclosed |
| US-7714013-B2 | Azole derivatives and fused bicyclic azole derivatives as therapeutic agents | TRANSTECH PHARMA, INC. (US) | 2010-05-11 | — | — | US | disclosed |
| CN-101613321-A | The list and the bicyclic pyrrole derivatives that suppress part and advanced glycation end product acceptor interaction | TRANSTECH PHARMA INC | 2009-12-30 | — | — | CN | disclosed |
| CN-101597262-A | The list and the bicyclic pyrrole derivatives that suppress part and advanced glycation end product acceptor interaction | TRANSTECH PHARMA INC (US) | 2009-12-09 | — | — | CN | disclosed |
| CN-100525763-C | Mono-and bicyclic pyrrole derivatives inhibiting ligand interaction with higher glycation end product receptors | TRANSTECH PHARMA INC (US) | 2009-08-12 | — | — | CN | disclosed |
| US-7361678-B2 | Azole derivatives and fused bicyclic azole derivatives as therapeutic agents | TRANSTECH PHARMA, INC. (US) | 2008-04-22 | — | — | US | disclosed |
| US-20070213347-A1 | Azole derivatives and fused bicyclic azole derivatives as therapeutic agents | TRANSTECH PHARMA (US) | 2007-09-13 | — | — | US | disclosed |
| US-20070021386-A1 | Azole derivatives and fused bicyclic azole derivatives as therapeutic agents | TRANSTECH PHARMA (US) | 2007-01-25 | — | — | US | disclosed |
| CN-1633290-A | Mono-and bicyclic pyrrole derivatives inhibiting ligand interaction with higher glycation end product receptors | TRANSTECH PHARMA INC (US) | 2005-06-29 | — | — | CN | disclosed |
| EP-1482931-A2 | MONO- AND BICYCLIC AZOLE DERIVATIVES THAT INHIBIT THE INTERACTION OF LIGANDS WITH RAGE | Transtech Pharma, Inc. (US) | 2004-12-08 | — | — | EP | disclosed |
| US-20040082542-A1 | Azole derivatives and fused bicyclic azole derivatives as therapeutic agents | VTV THERAPEUTICS LLC | 2004-04-29 | — | — | US | disclosed |
| WO-2003075921-A2 | MONO- AND BICYCLIC AZOLE DERIVATIVES THAT INHIBIT THE INTERACTION OF LIGANDS WITH RAGE | TRANSTECH PHARMA, INC. (US) | 2003-09-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100256119-A1 | Azole derivatives and fused bicyclic azole derivatives as therapeutic agents | AGER, S100A4, S100B | TSHR 3842/4885USP2 4446/4885KDM4E 4107/4885 |
| US-20040082542-A1 | Azole derivatives and fused bicyclic azole derivatives as therapeutic agents | AGER, S100A4, S100B | TSHR 3917/4885USP2 4405/4885KDM4E 3968/4885 |
| US-20070021386-A1 | Azole derivatives and fused bicyclic azole derivatives as therapeutic agents | AGER, S100A4, S100B | TSHR 3767/4885USP2 4348/4885KDM4E 4138/4885 |
| US-20120088778-A1 | AZOLE DERIVATIVES AND FUSED BICYCLIC AZOLE DERIVATIVES AS THERAPEUTIC AGENTS | AGER, S100A4, S100B | TSHR 3767/4885USP2 4348/4885KDM4E 4138/4885 |
| US-20070213347-A1 | Azole derivatives and fused bicyclic azole derivatives as therapeutic agents | AGER, S100A4, S100B | TSHR 3767/4885USP2 4348/4885KDM4E 4138/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.